Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Sommermeyer

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Journal of Molecular Medicine (Berlin, Germany)|March 13, 2008
Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassetteMatthias Leisegang, Boris Engels, Peter Meyerhuber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2013
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cellsMichael Hudecek, Maria-Teresa Lupo-Stanghellini, Paula L Kosasih, et al.
Cancer Immunology Research|September 13, 2014
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activityMichael Hudecek, Daniel Sommermeyer, Paula L Kosasih, et al.
Journal of Molecular Biology|August 20, 2013
Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexesSheena N Smith, Daniel Sommermeyer, Kurt H Piepenbrink, et al.
Cancer Immunology Research|October 31, 2014
Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cellsCarolina Berger, Daniel Sommermeyer, Michael Hudecek, et al.
Cancer Journal (Sudbury, Mass.)|March 27, 2014
Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset compositionStanley R Riddell, Daniel Sommermeyer, Carolina Berger, et al.
Blood|July 10, 2009
Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional aviditySusanne Wilde, Daniel Sommermeyer, Bernhard Frankenberger, et al.
European Journal of Immunology|October 20, 2006
Designer T cells by T cell receptor replacementDaniel Sommermeyer, Julia Neudorfer, Monika Weinhold, et al.
The Journal of Clinical Investigation|November 2, 2016
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasiaPaulina J Paszkiewicz, Simon P Fräßle, Shivani Srivastava, et al.
Cancers|April 23, 2022
T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor ReactivityNadja Sailer, Ina Fetzer, Melanie Salvermoser, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Journal of Molecular Medicine (Berlin, Germany)|March 13, 2008
Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassetteMatthias Leisegang, Boris Engels, Peter Meyerhuber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2013
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cellsMichael Hudecek, Maria-Teresa Lupo-Stanghellini, Paula L Kosasih, et al.
Cancer Immunology Research|September 13, 2014
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activityMichael Hudecek, Daniel Sommermeyer, Paula L Kosasih, et al.
Journal of Molecular Biology|August 20, 2013
Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexesSheena N Smith, Daniel Sommermeyer, Kurt H Piepenbrink, et al.
Cancer Immunology Research|October 31, 2014
Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cellsCarolina Berger, Daniel Sommermeyer, Michael Hudecek, et al.
Cancer Journal (Sudbury, Mass.)|March 27, 2014
Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset compositionStanley R Riddell, Daniel Sommermeyer, Carolina Berger, et al.
Blood|July 10, 2009
Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional aviditySusanne Wilde, Daniel Sommermeyer, Bernhard Frankenberger, et al.
European Journal of Immunology|October 20, 2006
Designer T cells by T cell receptor replacementDaniel Sommermeyer, Julia Neudorfer, Monika Weinhold, et al.
The Journal of Clinical Investigation|November 2, 2016
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasiaPaulina J Paszkiewicz, Simon P Fräßle, Shivani Srivastava, et al.
Cancers|April 23, 2022
T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor ReactivityNadja Sailer, Ina Fetzer, Melanie Salvermoser, et al.
Pageof 3